Stock Scorecard



Stock Summary for Zymeworks BC Inc (ZYME) - $27.73 as of 4/16/2026 11:57:44 AM EST

Total Score

8 out of 30

Safety Score

41 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ZYME

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ZYME

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ZYME

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ZYME

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ZYME (41 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ZYME

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results 3/6/2026 8:10:00 PM
Zymeworks (NASDAQ: ZYME) posts 39% 2025 revenue growth, narrows loss 3/6/2026 4:39:00 PM
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript 3/3/2026 12:53:00 PM
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results 3/3/2026 7:10:00 AM
Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing 3/2/2026 11:29:00 AM
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? 12/11/2025 11:09:00 PM
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? 12/10/2025 8:08:00 PM
Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study 11/18/2025 12:57:00 PM
Zymeworks stock hits four-year high on promising results from digestive cancer trial 11/17/2025 9:09:00 PM
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients 11/17/2025 8:08:00 PM

Financial Details for ZYME

Company Overview

Ticker ZYME
Company Name Zymeworks BC Inc
Country USA
Description Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/14/2026

Stock Price History

Last Day Price 27.73
Price 4 Years Ago 7.86
Last Day Price Updated 4/16/2026 11:57:44 AM EST
Last Day Volume 790,519
Average Daily Volume 728,373
52-Week High 28.49
52-Week Low 10.86
Last Price to 52 Week Low 155.34%

Valuation Measures

Trailing PE N/A
Industry PE 30.70
Sector PE 33.83
5-Year Average PE -7.81
Free Cash Flow Ratio 49.52
Industry Free Cash Flow Ratio 20.00
Sector Free Cash Flow Ratio 25.19
Current Ratio Most Recent Quarter 5.52
Total Cash Per Share 0.56
Book Value Per Share Most Recent Quarter 3.60
Price to Book Ratio 7.69
Industry Price to Book Ratio 82.10
Sector Price to Book Ratio 25.25
Price to Sales Ratio Twelve Trailing Months 19.49
Industry Price to Sales Ratio Twelve Trailing Months 8.76
Sector Price to Sales Ratio Twelve Trailing Months 4.40
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 73,750,000
Market Capitalization 2,045,087,500
Institutional Ownership 99.43%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 33.88%
Reported EPS 12 Trailing Months -1.08
Reported EPS Past Year -1.08
Reported EPS Prior Year -1.61
Net Income Twelve Trailing Months -81,130,000
Net Income Past Year -81,130,000
Net Income Prior Year -122,695,000
Quarterly Revenue Growth YOY -91.90%
5-Year Revenue Growth 22.16%
Operating Margin Twelve Trailing Months -1,756.00%

Balance Sheet

Total Cash Most Recent Quarter 41,157,000
Total Cash Past Year 41,157,000
Total Cash Prior Year 66,103,000
Net Cash Position Most Recent Quarter 41,157,000
Net Cash Position Past Year 41,157,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 268,501,000
Total Stockholder Equity Prior Year 338,768,000
Total Stockholder Equity Most Recent Quarter 268,501,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -34,930,150
Free Cash Flow Per Share Twelve Trailing Months -0.47
Free Cash Flow Past Year -34,526,000
Free Cash Flow Prior Year -113,110,000

Options

Put/Call Ratio 142.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.93
MACD Signal 0.71
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.20
RSI 69.19
50-Day SMA 13.27
150-Day SMA 0.00
200-Day SMA 11.85

System

Modified 4/18/2026 11:06:06 AM EST